Navigation Links
Tris Pharma Hires President for Generic Pharmaceuticals Business
Date:6/20/2013

MONMOUTH JUNCTION, N.J., June 20, 2013 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that it has named Janet Penner as President of its new generic pharmaceuticals business.   

Tris' generic pharmaceuticals business, with its own distinct sales, marketing and distribution, will be responsible for commercializing Tris' Abbreviated New Drug Applications (ANDAs) while leveraging Tris' considerable manufacturing capabilities. Tris currently has 13 FDA-approved ANDA products, including several 'first-to-market' generics. All of Tris' generic products are manufactured in its FDA-inspected, state-of-the art 130,000-square-foot facility in New Jersey.  

"Tris' generics initiative is a natural evolution of the overall strategic vision at Tris; bringing technologically-challenging, high-quality products to the marketplace," said Ketan Mehta, President and CEO of Tris Pharma.

Janet comes to Tris with a wealth of expertise in the commercialization of generic products. She brings nearly 15 years of experience in leadership roles within the generic pharmaceuticals industry, including AmerisourceBergen, where she was responsible for the purchasing of generic pharmaceuticals. Most recently, Janet headed sales & marketing at CorePharma. Janet has also held various positions of growing responsibility at General Electric and PepsiCo, and holds an MBA.

"Tris' unique technology for liquid sustained-release products, along with the continued expansion of its strategic pipeline of both liquid and solid oral dosage ANDA development projects, has me truly excited to spearhead the generic pharmaceuticals business at Tris," said Ms. Penner.

About Tris Pharma
Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies-driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, U.S.A. For more information, please visit http://www.trispharma.com.


'/>"/>
SOURCE Tris Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2019)... ... 13, 2019 , ... The Allergenic Products Advisory Committee of the Food and ... data, to recommend approval of a standardized oral immunotherapy (OIT) product for peanut allergy. ... as AR101. , The FDA would require a Risk Evaluation and Mitigation Strategy (REMS) ...
(Date:9/14/2019)... ... September 14, 2019 , ... ... plaintiffs living with peritoneal mesothelioma, a jury in Middlesex County found Johnson & ... of plaintiffs alleging their mesotheliomas were caused by asbestos-containing J&J talc products. ...
(Date:9/12/2019)... ... September 12, 2019 , ... ... help make the services of CPESN’s clinically integrated network of more than 2,400 ... CPESN USA’s participating pharmacies provide high quality clinical service programs that will now ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... September 17, 2019 , ... Caravan Health ... organization (ACO) in the country, the company announced today. High-performing community health systems ... quality and increase cost efficiency. This opportunity is open to those new to ...
(Date:9/17/2019)... , ... September 17, 2019 , ... ... availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol ... protocols to understand the scope of their EHS regulatory obligations and rapidly collect, ...
(Date:9/17/2019)... (PRWEB) , ... September 17, ... ... host the October 18 "Pacifica Experience" Open House day on Pacifica's Lambert ... doctoral degree programs in Depth Psychology, the Humanities, Clinical Psychology, Counseling Psychology, ...
(Date:9/11/2019)... (PRWEB) , ... September 12, 2019 , ... “Heart Seizures”: ... with diagnosed coronary artery disease as he hopes to prevent anyone from having it ... of published author John Saltwick, a writer who was diagnosed with coronary artery disease. ...
(Date:9/11/2019)... ... 11, 2019 , ... The 2019 Minnesota Anatomic Complex Knee ... Mall of America Radisson Blu. Four experts from Twin Cities Orthopedics (TCO), including ... conference, which brings together more than 100 national and international orthopedic surgeons for ...
Breaking Medicine News(10 mins):